The Cancer EPIgenetics and iMMunotherapY team (CEPIMMY) has been created in January 2023 through a Chair of Excellence from the Laboratory of Excellence for Innovation in Signal Transduction Pathways in Life Sciences (Labex SIGNALIFE), a program of excellence hosted by the Université Côte d’Azur. The team focuses on hematological malignancies, which are common and aggressive cancers with limited treatment options. Our research interests are categorized in three axes: 1) investigating the mechanistic events underpinning the development and progression of blood cancers caused by malfunctioning of epigenetic processes, 2) exploring new combinatorial epigenetic therapies and 3) understanding how epigenetic mechanisms modulate the dynamic cellular interactions between the tumor and the (innate) immune system.

Our research vision integrates basic and translational approaches, combining epigenetic-focused themes as well as human systems, mouse models and innovative methods to investigate the causes of blood cancer and enhance the applicability of epigenetic therapies and immunotherapies.

equipe 14


Recruiting International Leaders in Oncology 2023

Our lab has been awarded the prestigious « Recruiting international leaders in oncology » Grant from the Fondation ARC. Through this program established in 2010, the Fondation ARC commits up to 1.5 million euros over a 5-year period to supporting one newly created team within a French research institute. More information here:



From February to June 2023, the team is hosting a 1st year Master student

My name is Calixte Calaud and I am from Burgundy. In Dijon I obtained a Bachelor’s degree in Cellular Biology and Physiology from the Université de Burgundy. Through years of study, I realized that I love genetics, and for that reason I moved to Nice to pursue a Master’s degree in Genetics and Development in the Université Côte d’Azur. I am currrently doing an internship in the new Team CEPIMMY led by Dr Pilar Dominguez. My project aims to investigate different combinatorial epigenetic therapies to treat diffuse large B-cell lymphomas.